<DOC>
	<DOCNO>NCT02216721</DOCNO>
	<brief_summary>Primary aldosteronism ( PA ) disorder adrenal gland cause autonomous overproduction mineralocorticoid , lead arterial hypertension . Although rare , frequent cause secondary hypertension . Early detection important avoid end organ damage , specifically cardiovascular metabolic morbidity . Recent study show positive correlation patient PA low bone density especially spine , significant improvement post treatment , either medically surgically . There also positive correlation high aldosterone renin ratio high level intact parathyroid hormone ( iPTH ) responsible cortical bone loss especially distal forearm . We hypothesize patient PA high level iPTH , low bone density especially distal forearm , improvement post treatment .</brief_summary>
	<brief_title>The Effect Disease-specific Treatment Bone Turnover Markers Patients With Primary Aldosteronism</brief_title>
	<detailed_description>In 2004 , animal model study , rat give aldosterone/salt treatment find reduction bone mineral density ( BMD ) cortical bone strength . This believe due hypermagnesuria hypercalciuria lead bone loss . This lead subsequent study find association PA low serum ionized calcium , increase urine calcium magnesium , raise intact parathyroid hormone ( PTH ) level subsequent low bone mineral density . In one small study 11 patient confirm PA take cohort 188 patient adrenal incidentaloma , BMD vertebral , total neck femur find low non-PA patient , high prevalence vertebral osteoporotic fracture ( 72.7 % among PA patient vs 20 % among non-PA patient ) . Serum PTH significantly high PA group compare non-PA group . Six month treatment either medically surgically lead significant decrease urinary calcium excretion PTH PA group . Lumbar spine BMD show significant improvement one year treatment 5 patient . The cross-sectional interventional data GECOH study , conduct tertiary center Austria patient confirm PA , look difference PTH level patient PA ( n=10 ) essential hypertension ( EH ) ( n=182 ) find PTH level significantly high PA patient compare EH group . Treatment either adrenalectomy mineralocorticoid receptor antagonist lead significant decrease PTH concentration . Both study significant difference serum Vitamin D level case control , well pre post treatment PA patient . However latter study , PTH reduction find significant PA patient underwent adrenalectomy compare patient treat medically mineralocorticoid receptor antagonist . A recent large-scale study 3000 German general adult population show significant non linear association aldosterone-renin ratio plasma PTH concentration , especially subject ARR &gt; 90th percentile , despite normal Vitamin D level . This believe due presence parathyroid receptor type 1 adrenal well parathyroid gland express mineralocorticoid receptor . However , calcium intake status well calcium level assess study . This find echoed study show positive association PTH level PA affect Vitamin D status . It well know high PTH level associate low bone mass higher osteoporotic fracture risk due stimulation effect PTH osteoclastic osteoblastic activity bone result release calcium phosphate bone . Up date , knowledge , study association PA bone turnover marker . The use sensitive marker surrogate indicator improvement bone mass pre post treatment patient PA either medically surgically novel . The relationship calcium intake patient bone metabolism blood parameter look previously . In addition , involvement peripheral cortical bone mass ( distal radius ) , usually associate elevated PTH , group patient study . In study , aim : 1 . Assess BMD vertebra , total femoral neck , distal third radius PA patient compare non-PA. 2 . Evaluate effect specific treatment bone turnover marker BMD patient PA 3 . Assess relationship BMD bone turnover marker serum iPTH , calcium , magnesium vitamin D level .</detailed_description>
	<mesh_term>Hyperaldosteronism</mesh_term>
	<criteria>1 . Age &gt; 18 year old 2 . Confirmed primary aldosteronism follow criterion ) Aldosteronerenin ratio &gt; 555 SI 30 ( aldosterone take pmol/L , renin ng/dL ) ii ) Aldosterone post fludrocortisone suppression test &gt; 166pmol/L &gt; 6ng/dL , iii ) Aldosterone post saline suppression test &gt; 277pmol/L &gt; 10ng/dL Exclusion Criteria 1 . Patients medication affect bone metabolism , eg bisphosphonates , hormonal replacement therapy , SERM , testosterone , antiandrogen , anticonvulsant , calcium Vitamin D 2 . Primary aldosteronism post treatment ( surgically medically spironolactone eplerenone ) 3 . Estimated GFR &lt; 30ml/min 4 . Severe hepatic failure 5 . Severe heart failure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>bone mineral density</keyword>
	<keyword>bone turnover marker</keyword>
	<keyword>primary aldosteronism treatment</keyword>
</DOC>